REVIEWARTICLE

5-HT$_{2A}$ Receptor: A Newer Target for Obesity

Jignesh Patel[1*], Krupali Mistry[2], Anirudh Jain [3]

1. Department of Pharmaceutics and Pharmaceutical Technology, SAL Institute of Pharmacy, Gujarat, India
2. Drug Inspector, Food and drug department,Gandhinagar, Gujarat, India.
3. Department of Pharmaceutics and Pharmaceutical Technology, SAL Institute of Pharmacy, Gujarat, India.

*Correspondence for Author:

Mr. Jignesh Patel

Asst.Professor,
SAL Institute of Pharmacy
Department of Pharmaceutics and Pharmaceutical Technology
Opp of Science City, Village: Bhadaj, Ahmedabad-380060, Gujarat, India
E mail: jigneshp712@gmail.com

ABSTRACT

Obesity has become major worldwide health problems. Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter that contributes to the regulation of many physiological processes and abnormalities of the serotonergic system have been implicated in the pathogenesis of obesity. 5-HT$_{2A}$ receptor is belongs to G-protein coupled receptor (GPCR), expressed widely throughout the central nervous system (CNS). Hypothalamic 5-HT$_{2A}$ receptors might have a role in the regulation of feeding and energy homeostasis. 5-HT$_{2A}$ receptor gene expression was increased in association with obesity. 5-HT$_{2A}$ receptor antagonism increases expression of adiponectin and decreases plasminogen activator inhibitor 1 (PAI-1) expression via the 5-HT$_{2A}$ receptor signaling cascade. Recently, development of 5-HT$_{2A}$ receptor antagonists as a novel therapeutic strategy for obesity and associated comorbidities has been the focus of much interest. Here, we describe the role of 5-HT$_{2A}$ receptor in pathogenesis of obesity.

Key words: Obesity, serotonin, 5-HT$_{2A}$ receptor, sarpogrelate, adiponectin, PAI-1

INTRODUCTION

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems [1]. Diet-induced obesity and the subsequent development of features of the metabolic syndrome have become major worldwide health problems. Almost 70% of adults in U.S.A. are overweight but, perhaps more alarmingly, 16% of juveniles are overweight [2]. The number of overweight individuals worldwide has reached 2.1 billion, leading to an explosion of obesity-related health problems associated with a high mortality rate [3]. Obesity is considered central to the metabolic syndrome and is associated with increases in the risk of an array of diseases, including insulin resistance, type 2 diabetes mellitus, fatty liver disease, atherosclerosis, cardiovascular disease, degenerative disorders, and some cancers [4]. Given that attempts to regulate food intake and content are futile in most of the at risk patients, a clearer understanding of the cellular events underlying the pathophysiology of the obesity is required to allow therapeutic synergism of novel medications along with diet and exercise [5]. Here, we try to emphasize on molecular regulation of 5-HT$_{2A}$ receptor in pathogenesis of obesity.

Serotonin (5-hydroxytryptamine; 5-HT) is a neurotransmitter that contributes to the regulation of many physiological processes such as sleep, appetite, and hormone secretion [6]. Abnormalities of the serotonergic system have been implicated in a number of human diseases including obesity [7]. Acute administration of serotonergic compounds altered the expression of peptidergic appetitive effectors within the hypothalamus, namely pro-opiomelanocortin (POMC) and neuropeptide Y (NPY). POMC and NPY are synthesized within discrete neuronal populations of the arcuate nucleus (ARC) of hypothalamus. Administration of serotonergic compounds causes an increase in anorectic POMC mRNA and a decrease in orexigenic NPY mRNA in arcuate nucleus [8]. Recently, it has been shown that manipulation of these first order hypothalamic POMC/cocaine and amphetamine regulated transcript (CART) and agouti-related protein (AgRP)/NPY neurons is a mechanism through which serotonergic compounds reduce food intake [9]. Specifically, the serotonin system concomitantly regulates the antagonistic functions of POMC/CART and AgRP/NPY neurons through two distinct G-protein coupled receptor subtypes: G$_q$-coupled 5-HT$_{2C}$ receptor and G$_i$-coupled 5-HT$_{1B}$ receptor [10]. 5-HT$_{2C}$ receptor depolarizes anorectic POMC/CART neurons and release α-melanocyte-stimulating hormone (α-MSH), which in turn activates second-order melanocortin 4 receptor (MC4R) of paraventricular nucleus of the hypothalamus [11]. Concomitant activation of 5-HT$_{1B}$ receptors expressed on orexigenic AgRP/NPY neurons within the ARC causes membrane hyperpolarization and subsequent

inhibition of neuropeptide release [12]. Inhibitory 5-HT$_{1B}$ receptor activation also attenuates inhibitory postsynaptic currents onto POMC/CART neurons and thereby further potentiating anorexigenesis [13].

Infusion of serotonin into the peraventricular hypothalamus (PVH) of rats reduces food intake [14]. Corticotropin-releasing hormone (CRH) neurons located within the PVH have been reported to express MC4R which is responsible for decrease in food intake [15]. CRH are directly innervated by serotonergic projections and CRH expression are stimulated by compounds increasing serotonergic efficacy [16]. It is possible that serotonin may directly influence the activity of these CRH MC4R-expressing cells and thereby reduces food intake. Thus, an increase in serotonin bioavailability (due to food intake or pharmacological compounds such as sibutramine and fenfluramine) or direct agonism of 5-HT$_{2C}$ receptors and 5-HT$_{1B}$ receptors modulates firing of POMC/CART neurons as well as AgRP/NPY neurons within the arcuate nucleus of the hypothalamus and thereby promotes satiety and the cessation of food intake [17] (Figure I).

Over the years, seven classes of serotonin (5-HT) receptors (5-HT$_1$ to 5-HT$_7$) have been identified that are divided into 14 subfamilies. The 5-HT$_2$ class includes three subtypes of G-protein-coupled receptors, classified as 5-HT$_{2A}$, 5-HT$_{2B}$ and 5-HT$_{2C}$ [18].


Figure I. Proposed model of a serotonergic pathway modulating food intake [17.]

5-HT$_{2A}$ receptors are expressed widely throughout the central nervous system (CNS) especially in cortex (mainly prefrontal, parietal, and somatosensory cortex), olfactory tubercle, midbrain, and cerebellum [19]. The high concentrations of 5-HT$_{2A}$ receptors on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, by enhancing glutamate release followed by a complex range of interactions with the 5-HT$_{1A}$, GABA$_A$, adenosine A$_1$, AMPA, mGluR$_{2/3}$, mGlu$_5$, and OX$_2$ receptors [20]. The 5-HT$_{2A}$ receptors have also been found in the Golgi cells of the granular layer, and in the Purkinje cells of cerebellum [21]. In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system [22].

The 5-HT$_{2A}$ receptor is coded by the *HTR2A* gene. In humans, *5-HT$_{2A}$* gene is located on 13q14-q21 on chromosome 13 and consists of three exons separated by two introns and spans over 20 kb[22]. More recent data suggest that the *Msp*I polymorphism of the *5-HT$_{2A}$* gene may influence food and alcohol intake in obese subjects [23]. Some studies have also been indicated a role of the -1438G/A variant of the *5-HT$_{2A}$* gene in the pathogenesis of anorexia nervosa [24]. The -1438G/A promoter variant is also involved in the pathogenesis of abdominal obesity & related perturbations in insulin, glucose and lipid metabolism as well as in regulation of circulating hormones including salivary cortisol [25].

5-HT$_{2A}$ receptors that belong to the super family of G-protein coupled receptors (Gαq-coupled receptors) [26]. The 5-HT$_{2A}$ receptors activate the phosphoinositide hydrolysis signaling cascade, leading to neuronal depolarization and increases in excitability [27]. Upon receptor stimulation with agonist, Gα$_q$ and β-γ subunits dissociate to initiate downstream effector pathways. Gα$_q$ stimulates phospholipase C (PLC) activity, results in phospholipase C (PLC)-mediated phosphatidylinositol (PI) lipid hydrolysis, which liberates the second messengers diacylglycerol (DAG) and inositol triphosphates (IP$_3$), which in turn stimulate protein kinase C (PKC) activity and Ca^{2+} release [28]. They share a high degree of amino acid sequence homology (68–79% in the transmembrane segments) and similar pharmacological profiles and signal transduction systems with other 5-HT$_2$ receptor subtypes (5-HT$_{2B}$ and 5-HT$_{2C}$ receptors) [29]. Activation of 5-HT$_{2A}$ excites GABAnergic interneurons in the dorsal raphe nucleus, leading to inhibition of serotonergic cell firing [30].

Ligands of 5-HT$_{2A}$ receptor include LSD, psilocin and mescaline act as full or partial agonists at 5-HT$_{2A}$ receptor, and represent the three main classes of 5-HT$_{2A}$ agonists, the ergolines,

tryptamines and phenethylamines, respectively [31]. Ketanserin is a 5-HT$_{2A}$ receptor antagonist with α_1-adrenoceptor blocking property [32].

Sarpogrelate is specific 5-HT$_{2A}$ receptor antagonist and has only insignificant 5-HT$_1$, 5-HT$_3$, 5-HT$_4$, α_1-adrenoceptor, α_2-adrenoceptor, α-adrenoceptor, H$_1$ and H$_2$-histaminic receptor, and M$_3$-muscarinic receptor antagonistic activities [33].

5-HT induced platelet activation and platelet aggregation is mediated by 5-HT$_{2A}$ receptor activation [34]. Acceleration of 5-HT mediated platelet activation at the site of vascular injury and vascular smooth muscle cell proliferation by 5-HT$_{2A}$ receptor activation leads to vascular occlusion. 5-HT$_{2A}$ receptor activation is also involved in the 5-HT-mediated increase in Ca$^{2+}_i$ and cause contraction of vascular smooth muscle cells [35]. Thrombotic and vasoconstrictor effects of 5-HT are mediated by 5-HT$_{2A}$ receptor activation [36]. Thus, 5-HT$_{2A}$ receptor is of significant clinical interest because of their potential involvement in mediating many cardiovascular diseases [37]. As 5-HT$_{2A}$ receptor is involved in numerous physiological functions and pathological conditions, it is possible that activating mutations of the 5-HT$_{2A}$ receptor might be responsible for mediating several pathophysiological effects in both the central and peripheral nervous systems [38].

5-HT$_{2A}$ Receptor in Obesity

Hypothalamic 5-HT$_{2A}$ receptors might have a role in the regulation of feeding and energy homeostasis. 5-HT$_{2A}$ receptors are likely to down-regulate POMC, CART, CRH, 5-HT$_{2C}$, and 5-HT$_{1B}$ receptor gene expression in the hypothalamus [39].

Hypothalamic 5-HT$_{2A}$ receptor gene expression was increased in association with obesity in A^y mice compared with wild type mice [40]. A^y mice have dominant alleles at the agouti locus (A), and display hyperphagia and obesity [41]. It was reported that pharmacologic inactivation of 5-HT$_{2A}$ receptors suppressed hyperphagia and body weight gain, leading to decreased blood glucose levels in obese A^y mice [42]. Hypothalamic 5-HT$_{2A}$ receptors might therefore be involved in the development of obesity and diabetes in A^y mice [43]. Sarpogrelate, a 5-HT$_{2A}$ receptor antagonist inactivates 5-HT$_{2A}$ receptors and interacts with POMC neurons in the hypothalamus. It stimulates POMC neurons to release enough α-MSH to overcome agouti blockade of MC receptors [44].

Inhibition of 5-HT might improve insulin sensitivity in diabetes. 5-HT$_{2A}$ receptor mediates hyperglycemic effects of 5-HT through the release of adrenaline from adrenal gland. Adrenaline increases hepatic glucose production and inhibits insulin secretion and the glucose uptake by tissue [45]. Increase in plasma 5-HT level as well as increase in 5-HT release from platelet was

observed in the diabetic patients. These will lead to increase sensitivity to 5-HT in diabetes and hyperglycemia will occur. Therefore, it is thought that inhibition of 5-HT$_{2A}$ might improve insulin sensitivity and thereby led to improvement of insulin resistance [46].

Adipose tissue participates in the regulation of energy homeostasis, immune responses, and hemostasis as an important endocrine organ that secretes adipokines [47]. In obesity, hypertrophic adipocytes decrease expression and secretion of adiponectin [48]. Adiponectin is an anti-diabetic and anti-atherogenic adipokine [49]. Human adipose tissue contributes to the elevation of plasma plasminogen activator inhibitor 1 (PAI-1) concentrations. PAI-1 plays important roles in the pathogenesis of cardiovascular events, promoting both thrombosis and fibrosis [50]. Among the active 5-HT receptors (1A, 1B, 1D, and 2A), the 5-HT$_{2A}$ receptor was more abundant in hypertrophic adipocytes [51]. Expression of 5-HT$_{2A}$ receptor mRNA was increased in hypertrophic 3T3-L1 adipocytes and in mesenteric adipose tissue of diabetic-obese mice, db/db mice, which exhibit decreased expression of adiponectin and increased expression of PAI-1 [52]. There is the involvement of the 5-HT$_{2A}$ receptor signaling cascade via mitogen-activated protein kinase (MAPK)-dependent pathways in the regulation of adiponectin and PAI-1 expression [53].

Knowledge of the regulatory factors associated with down-regulation of adiponectin gene expression and up-regulation of PAI-1 gene expression is crucial for understanding the pathophysiological basis of obesity and metabolic diseases and could establish new treatment strategies for these conditions [54]. Adiponectin has insulin-sensitizing actions and obesity decreases adiponectin sensitivity, thereby leading to insulin resistance, which in turn aggravates hyperinsulinemia [55]. Expression of PAI-1 was increased in hypertrophic 3T3-L1 adipocytes, which produced a decrease in adiponectin expression. These results are consistent with the adipocyte dysfunction shown in obesity and type2 diabetes [56]. Sarpogrelate increases adiponectin expression [57]. This augmentation was inhibited by suppression of the 5-HT$_{2A}$ receptor gene using siRNA and suppression of this gene also increased adiponectin expression [58]. 5-HT$_{2A}$ stimulation activates Gq protein coupled to the 5-HT$_{2A}$ receptor, decreased adiponectin expression. These findings indicate that the 5-HT$_{2A}$ receptor signaling cascade negatively regulates adiponectin expression [59]. Moreover, expression of the 5-HT$_{2A}$ receptor was up-regulated in the adipose tissue of db/db mice and 3T3-L1 hypertrophic adipocytes, in which adiponectin expression was down-regulated and PAI-1 expression was up-regulated. So, there is possibility that the increase in 5-HT$_{2A}$ receptor expression in hypertrophic adipocytes is at least partially responsible for the

obesity-linked reduction in adiponectin expression. Long-lasting 5-HT$_{2A}$ receptor blockade might increase adiponectin expression down-regulated in obesity [60]. Transcriptional activity of PPAR gamma which increases adiponectin levels has been reported to decrease by MAPK phosphorylation [61]. 5-HT$_{2A}$ receptor stimulates MAPK in pulmonary artery fibroblasts which cause proliferative signals. 5-HT$_{2A}$ receptor stimulation may decrease the expression of adiponectin by reduction in the transcriptional activity of PPAR gamma through activation of MAPK in adipocytes [62]. The 5-HT$_{2A}$ receptor signaling cascade could modulate PAI-1 expression through MAPK pathway activation in adipocytes. Arrestin binds to the 5-HT$_{2A}$ receptor. It has been reported that arrestin binding to GPCR enables MAPK activation which is related to increase in PAI-1 gene expression in kidney [63].

In summary, 5-HT$_{2A}$ receptor gene expression was increased in association with obesity. 5-HT$_{2A}$ receptor antagonism increases expression of adiponectin and decreases PAI-1 expression via the 5-HT$_{2A}$ receptor signaling cascade. Antagonism of 5-HT$_{2A}$ receptors has the potential to protect against risk factors for and contribute to the treatment of cardiovascular diseases associated with metabolic syndrome as a result of obesity-related, aberrant adipocytokine metabolism. Additional research is required to determine the more precise role of 5-HT$_{2A}$ receptor in obesity and related complications. Such further research investigating the down- and upstream pathways through which serotonin influences appetite may yield additional pharmacological targets for the treatment of obesity.

REFERENCES:

1. Haslam DW, James WP: Obesity. Lancet, 2005, 366, 1197–1209.

2. Reaven GM: The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr, 2005, 25, 391–406.

3. Sebekova K, Raucinova M, Dzurik R: Serotonin metabolism in patients with decreased renal function. Nephron, 1989, 53, 229–232.

4. Huang XF, Han M, Huang X, Zavitsanou K, Deng C: Olanzapine differentially affects 5-HT$_{2A}$ and 5-HT$_{2C}$ receptor mRNA expression in the rat brain. Behav Brain Res, 2006, 171, 355–362.

5. Vitale ML, Chiocchio SR: Serotonin, a neurotransmitter involved in the regulation of luteinizing hormone release. Endocr Rev, 1993, 14, 480–493.

6. Haider S, Haleem DJ: Decreases of brain serotonin following a food restriction schedule of 4 weeks in male and female rats. Med Sci Monit, 2000, 6, 1061–1067.

7. Haleem DJ, Haider S: Food restriction decreases serotonin and its synthesis rate in the hypothalamus. Neuroreport, 1996, 7, 1153–1156.

8. Boston BA, Blaydon KM, Varnerin J, Cone RD: Independent and additive effects of central POMC and leptin pathways on murine obesity. Science, 1997, 278, 1641–1644.

9. Elias CF, Lee CE, Kelly JF, Ahima RS, Kuhar M, Saper CB, Elmquist JK: Characterization of CART neurons in the rat and human hypothalamus. J Com Neurol, 2001, 432, 1–19.

10. Seuwen K, Magnaldo I, Pouyssegur J: Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT$_{1B}$ receptors coupled to a Gi-protein. Nature, 1988, 335, 254–256.

11. Sharma SK, Takeda N, Arneja AS, Dhalla NS: Sarpogrelate inhibits genes involved in vascular neointimal hyperplasia and remodeling. Atheroscler Hypertens diab, 2003, 98, 175–186.

12. Lucas JL, Yamamoto A, Hen R: Absence of fenfluramine-induced anorexia and reduced c-fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice. J Neurosci, 1998, 18, 5537–5544.

13. Sharma SK, Zahradka P, Chapman D, Kumamoto H, Takeda N, Dhalla NS: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther, 1999, 290: 1475–1481.

14. Shibano T, Tanaka T, Morishima Y, Yasuoka M, Fujii F: Pharmacological profile of a new 5-hydroxytryptamine 2 receptor antagonist, DV-7028. Arch Int Pharmacodyn Ther, 1992, 319, 114–128.

15. Stoving RK, Hangaard J, Hansen-Nord M, Hagen C: A review of endocrine changes in anorexia nervosa. J Psychiatr Res, 2000, 33, 139–152.

16. Leibowitz SF: Brain monoamines and peptides: role in the control of eating behavior. Fed Proc, 1986, 45, 1396–1403.

17. Garfield AS, Heisler LK: Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol, 2009, 587, 49–60.

18. Saxena PR: Serotonin receptors: Subtypes, functional responses and therapeutic relevance. Pharmacol Ther, 1995, 66, 339–368.

19. Takada Y, Takada A, Urano T: MCI-9042, the new selective antagonist of serotonergic (5-HT$_{2A}$) receptors. Cardiovasc Drug Rev, 1997, 15, 101–121.

20. Shimizu Y, Minatoguchi S, Hashimoto K: The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts. J Am Coll Cardiol, 2002, 40, 1347–1355.

21. Halford JC, Blundell JE: Separate systems for serotonin and leptin in appetite control. Ann Med, 2000, 32, 222–232.

22. Shouzu A, Nomura S, Hayakawa T: Effect of sarpogrelate hydrochloride on platelet-derived microparticles and various soluble adhesion molecules in diabetes mellitus. Clin Appl Thromb Hemost, 2000, 6, 139–143.

23. Sikorski BW, Hodgson WC, King RG: Thromboxane A2 receptor stimulation similarly potentiates pressor responses to 5-hydroxytryptamine in perfused hindquarters of non-diabetic and alloxan diabetic rats. Clin Exp Pharmacol Physiol, 1991, 18, 237–244.

24. Simpson PJ, Schelm JA, Jakubowski JA, Smallwood JK: The role of serotonin (5HT$_2$) receptor blockade in myocardial reperfusion injury: Effects of LY53857 in a canine model of myocardial infarction. J Pharmacol Exp Ther, 1991, 258: 979–985.

25. Smulders YM: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: The pivotal role of pulmonary vasoconstriction. Cardiovasc Res, 2000, 48, 23–33.

26. Stassen FR, Fazzi GE, Leenders PJ, Smits JF: Coronary arterial hyperreactivity and mesenteric arterial hyporeactivity after myocardial infarction in the rat. J Cardiovasc Pharmacol, 1997, 29, 780–788.

27. Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD: Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycemic control. Thromb Haemost, 1994, 72, 979–984.

28. Steyn DW, Odendaal HJ: Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet, 1997, 350, 1267–1271.

29. Borsini F, Bendotti C, Carli M., Poggesi E, Cohen H: The roles of brain noradrenaline and dopamine in the anorectic activity of diethylpropion in rats: a comparison with d-amphetamine. Res Commun Chem Patho Pharmacol, 1992, 26: 3–11.

30. Leibowitz SF, Brown LL: Histochemical and pharmacological analysis of catecholaminergic projections to the periformical hypothalamus in relation of feeding inhibition. Brain Res, 1980, 201, 315–345.

31. Yamanda J, Sugimoto Y, Ujikawa M: The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice. Eur J Pharmacol, 1999, 383, 49–51.

32. Serruys PW, Klein W, Tijssen JP: Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. Circulation, 1993, 88, 1588–1601.

33. Shimazu T, Noma M, Saito M: Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res, 1986, 369, 215–223.

34. Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR: Ultrastructural localization of serotonin 2A receptors in the middle layers of the rat prelimbic prefrontal cortex. Neuroscience, 2003, 116, 107–117.

35. Nichols DE, Nichols CD: Serotonin receptors. Chem Rev, 2008, 108, 1614–1641.

36. Welsh DJ, Harnett M, MacLean M, Peacock AJ: Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine 2A receptor and transporter. Am J Respir Crit Care Med, 2004, 170, 252–259.

37. Arita Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun, 1999, 257, 79–83.

38. Collin M, Hakansson OM, Misane I, Ogren SO, Meister BL: Decreased 5-HT transporter mRNA in neurons of the dorsal raphe nucleus and behavioral depression in the obese leptin deficient ob/ob mouse. Mol Brain Res, 2000, 81, 51–61.

39. Finn PD, Cunningham MJ, Rickard DG, Clifton DK, Steiner RA: Serotonergic neurons are targets for leptin in the monkey. J Clin Endocrinol Metab, 2001, 86, 422–426.

40. Ebihara K, Ogawa Y, Katsuura G, Numata Y, Masuzaki H, Satoh N, Tamaki M: Involvement of agouti related protein an endogenous antagonist of hypothalamic melanocortin receptor in leptin action. Diabetes, 1999, 48, 2028–2033.

41. Dryden S, Brown M, King P, Williams G: Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab, 1999, 31, 363–366.

42. Calapai G, Corica F, Sautebin L, Campo GM, Buemi M, Mauro VN: Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest, 1999,104, 975–982.

43. Nonogaki K, Nozue K, Oka Y: Increased hypothalamic 5-HT$_{2A}$ receptor gene expression and effects of pharmacologic 5-HT$_{2A}$ receptor inactivation in obese A^{y} mice. Biochem Biophy Res Commun, 2006, 351, 1078–1082.

44. Kokubu N: Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J, 2006, 70, 1451–1456.

45. Harris RB, Zhou J, Redmann SM, Smagin GN, Smith SR, Rodgers E, Zachwieja JJ: A leptin dose-response study in obese (ob/ob) and lean mice. Endocrinology, 1998, 139, 8–19.

46. Currie PJ, Coscina DV: Metergoline potentiates natural feeding and antagonizes the anorectic action of medial hypothalamic 5-hydroxytryptamine. Pharmacol Biochem Behav, 1996, 53, 1023–1028.

47. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab, 2004, 89, 2548–2556.

48. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type 1 and coronary artery disease. New Engl J Med, 2000, 342, 1792–1801.

49. Yamauchi T: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 2002, 8, 1288–1295.

50. Kawano H: Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood, 2001, 97, 1697–1702.

51. Hoyer D, Clarke DE, Fozard JR: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev, 1994, 46, 157–203.

52. Knight G, Boulton AJ, Drury J, Ward JD: Long term glycaemic control by alternative regimens in a feasibility study of continuous subcutaneous insulin infusion. Diabetes Res, 1986, 3, 355–358.

53. Goicolea OI, Hernandez CI, Garcia JA: Comparative study between the subcutaneous continuous insulin infusion pump and optimized conventional treatment: effects at 6 months. Rev Clin Esp, 1986, 179, 3–7.

54. Olsen T, Richelsen B, Ehlers N, Beck-Nielsen H: Diabetic retinopathy after 3 years treatment with continuous subcutaneous insulin infusion (CSII). Acta Ophthalmol, 1987, 65, 185–189.

55. Fang X, Sweeney G: Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem Soc Transac, 2006, 34, 798-799.

56. Dahl JS, Toriesen P, Hanssen K, Sandvik L, Aagenes O: Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes, 1987, 36, 1–5.

57. Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H: Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects: comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year follow-up. Horm Metab Res, 1987, 19, 419–421.

58. Kokubu N: Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease. Circ J, 2006, 70, 1451–1456.

59. Cerrito F, Lazzaro MP, Gaudio E, Arminio P, Aloisi G: 5HT$_2$-receptors and serotonin release: their role in human platelet aggregation. Life Sci, 1993, 53, 209–215.

60. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T: 5-HT$_{2A}$ receptor antagonist increases circulating adiponectin in patients with type 2 diabetes. Blood Coagul Fibrinolysis, 2005, 16, 423–428.

61. Kadowaki T: The role of PPAR gamma in high-fat diet-induced obesity and insulin resistance. J Diabetes Complications, 2002, 16, 41–45.

62. Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev, 2005, 26, 439–451.

63. Nerurkar SS: P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1. Biomark, 2007, 12, 87–112.